[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Clermont-Ferrand\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":624},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,142,0,25,[9,42,66,90,114,136,158,178,201,221,249,275,298,323,353,374,403,432,456,474,492,522,544,573,596],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100506209","validation-of-visual-analog-scales-to-measure-satisfaction-and-well-being-at-work-sowell-vas-100506209",false,"NCT05871411","Validation of Visual Analog Scales to Measure SatisfactiOn and WELL-being at Work (SoWell-VAS)","SoWell-VAS","Inclusion Criteria:\n\n* All voluntary adults with a professional activity.\n\nExclusion Criteria:\n\n* Minor\n* Person not volunteer to participate.\n* Protected adults (curatorship, guardianship, safeguard of justice)","ALL","18 Years","80 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","We spend a third of our life at work. Psychosocial risks (PSR) are a major issue in occupational health 1. Approaching the different dimensions of PSR calls on a dozen essential components: workload, autonomy, social support, burnout, anxiety, efforts made, rewards, work addiction, investment, etc. a specific questionnaire which usually contains 20 to 30 questions, so that having an overall view of PSR using the current reference questionnaires (Karasek, Siegrist, etc.) represents a total of more than 300 questions. The response time is thus incompatible with current medical practice (passage in the waiting room before the occupational health medical examination) and leads to a majority of non-responses during anonymous questionnaires on the Internet. On the other hand, these validated questionnaires were carried out by different people and are very heterogeneous between them, including in their formulation, so that the respondents have the impression of disorganization and anarchy. There is therefore a need for short, quick and uniform questionnaires. EVAs offer the incredible advantage of meeting these criteria: speed, uniformity, precision. From a data analysis point of view, EVAs also have the advantage of offering a continuous quantitative response, allowing the use of all statistical approaches. If some questionnaires have already been validated in the form of EVA, such as the EVA stress versus the \" Perceived Stress Scale \" questionnaire (PSS), the EVA workload and EVA autonomy at work versus the Karasek questionnaire, the other reference questionnaires are not yet validated in EVA (burnout, anxiety, efforts \u002F rewards, work addiction, etc.).",[26,27,28],"Validation","Visual Analogue Scale","Occupational Stress","RECRUITING","2026-08-05",{"date":32,"type":33},"2026-08-07","ACTUAL",{"date":35,"type":33},"2023-06-13",{"date":37,"type":22},"2028-06",{"name":39,"class":40},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100636765","evaluation-of-treatments-for-sore-throat-associated-with-acute-pharyngitis-andor-viral-tonsillitis-100636765","NCT07569939","Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and\u002For Viral Tonsillitis","PharyTol","Inclusion Criteria:\n\n* Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment\n* Bacterial rhinopharyngitis with negative TROD test\n* Effective contraception for female patients of childbearing age\n* Cooperation and sufficient understanding to comply with the requirements of the trial\n* Acceptance of registration in the SI-RIPH database\n* Having received informed information and agreeing to give written consent\n* Affiliated with the French Social Security scheme.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fprevious allergy to any of the product components,\n* Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough,\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…),\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent otorhinolaryngology surgery (\\\u003C6 months),\n* Pulmonary pathology (Chronic Obstructive Pulmonary Disease, asthma…),\n* Immunosuppression (according to patient's report),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","70 Years",{"count":51,"type":22},160,"INTERVENTIONAL",[54],"NA","The objective of this study is to conduct post-marketing clinical follow-up of four products: HMG, PHN, PHR, and TUR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of sore throats related to acute pharyngitis and\u002For viral-origin tonsillitis, while also assessing the benefit\u002Frisk ratio of the products.",[57,58],"Acute Pharyngitis","Viral Sore Throat","2026-08-03",{"date":30,"type":33},{"date":62,"type":33},"2026-07-29",{"date":64,"type":22},"2028-01",{"name":39,"class":40},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":23,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100649887","prevalence-of-brief-suicidal-crisis-in-psychiatric-settings-100649887","NCT07740356","Prevalence of Brief Suicidal Crisis in Psychiatric Settings","RBSCP","Inclusion Criteria:\n\n* Any adult patient consulting the psychiatrist in his\u002Fher office during the recruitment period, regardless of the reason for the consultation, and who has given consent to participate in this study.\n\nExclusion Criteria:\n\n* Minor patients, or patients who refuse to participate in the study.\n* Patients who have already completed the self-administered questionnaires previously (e.g., a second consultation within the same week).\n* Patients unable to understand and complete the self-administered questionnaires (cognitive impairment, difficulty understanding French, etc.).",{"count":74,"type":22},150,"1 Day","France is among the countries with one of the highest suicide rates in the world, far above those of its neighboring countries \\[Wasserman et al., 2012\\]. Suicide is the second leading cause of death among 15-24-year-olds, just after road traffic accidents, and the leading cause of death among 25-34-year-olds. Current models emphasize the variability of suicidal trajectories and the possible fluctuation in the duration of suicidal crises: for some individuals, the crisis evolves rapidly and explosively (brief), whereas for others, distress becomes more chronic, often in connection with underlying psychiatric disorders \\[Stanley, Brodsky, and Monahan, 2023\\]. In this context, the concept of a 'brief suicidal crisis' is an emerging one in psychiatry. It is characterized by an acute phase of psychological vulnerability, during which the main risk is progression to suicidal behavior, but it remains a temporary and reversible psychic crisis (lasting less than 24 hours). The crisis state is marked by a sudden inability to mobilize one's usual coping resources in the face of difficulties, making the individual highly vulnerable. Nevertheless, this concept has been little described, and a better assessment seems desirable, particularly in populations consulting a psychiatrist. Indeed, around 25% of people who die by suicide had consulted a psychiatrist in the month before their death \\[Luoma et al., 2002\\], yet few data are available on this topic.\n\nPrimary objective is to assess the prevalence of brief suicidal crisis episodes (lasting less than 24 hours) over the past 12 months among patients attending outpatient psychiatric care and within a sample of patients from a population catchment area in the Clermont-Ferrand region.",[78,79],"Suicidal Crisis","Psychiatric Disorder",[81],"suicidal crisis","2026-07-30",{"date":84,"type":33},"2026-07-31",{"date":86,"type":22},"2026-09-01",{"date":88,"type":22},"2026-12-31",{"name":39,"class":40},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":52,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},"100629189","concordance-between-inflammatory-activity-assessed-by-enteric-mri-with-and-without-intestinal-distension-product-in-patients-with-ileal-crohns-disease-100629189","NCT07471438","Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.","Study of Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.","CONFORT","Inclusion Criteria:\n\n* Patients with Crohn's disease according to European recommendations (ECCO) ≥ 18 years of age\n* With known or suspected ileal ± colonic involvement\n* Requiring reassessment of disease inflammatory activity according to the clinician\n* Able to give informed consent to participate in the research.\n* Affiliation with a Social Security scheme\n* Agreeing to undergo two MRIs in the same week\n\nExclusion Criteria:\n\n* Isolated colonic Crohn's disease\n* Resection \\> 1 m of small intestine\n* Severe obstructive symptoms defined according to CDOS (Crohn's disease obstructive symptoms score)\n* Uncontrolled intra-abdominal abscess\n* Isolated anoperineal lesions\n* Prevention of postoperative endoscopic recurrence\n* Temporary or permanent stoma\n* Total colectomy\n* Contraindication to MRI\n* Pregnant or breastfeeding women\n* Protected adults (under guardianship, trusteeship, family authorization, future protection mandate, with representation relating to the person)",{"count":99,"type":22},60,[54],"Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can significantly impair patients' quality of life. Due to its transmural nature (affecting the entire thickness of the intestinal wall), it naturally progresses to intestinal destruction (stenosis, fistula), requiring intestinal resection in approximately half of patients during follow-up. The long-term goal for patients is to maintain a normal life, i.e., without symptoms and without intestinal destruction. To this end, short- and medium-term therapeutic goals have evolved in recent years. Clinical remission is not a sufficient goal, as it has not changed the natural history of the disease. The current goal is to achieve a combination of clinical remission and endoscopic mucosal healing, as this is associated with a reduced risk of adverse outcomes (recurrence of symptoms, hospitalization, intestinal resection).\n\nTransmural healing assessed by MRI is also a promising goal associated with a reduced risk of adverse outcomes (recurrence of symptoms, hospitalization, intestinal resection). Furthermore, it is associated with a lower risk of progression to intestinal destruction, unlike endoscopic remission. In this context, transmural healing could soon become the benchmark in terms of therapeutic objectives for Crohn's disease, particularly in the ileum. Although enteric MRI is better accepted than colonoscopy by patients with Crohn's disease, in the ACCEPT1 study, nearly half of patients (48.6%) reported the need to use an intestinal distension product (PEG, mannitol, etc.) as a significant obstacle to repeating entero-MRI, while more than a third complained of vomiting (33.7%) or severe diarrhea (35.0%) induced by these same products. Being able to do without the use of distension products would significantly improve the acceptability of entero-MRI.\n\nThe investigators hypothesize that an enteric MRI without distension would lead to poorer ileal distension but would allow inflammatory activity scores to be assessed on MRI in a manner similar to an examination with distension, and thus would not impact the need for therapeutic intensification.",[103],"Crohn Disease (CD)",[105,106],"Crohn Disease","MRI",{"date":82,"type":33},{"date":109,"type":33},"2026-04-22",{"date":111,"type":22},"2026-09",{"name":39,"class":40},2,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":41},"100614360","evaluation-of-heart-failure-telemonitoring-eligibility-criteria-100614360","NCT07278583","Evaluation of Heart Failure Telemonitoring Eligibility Criteria","Evaluation of Eligibility Criteria for Heart Failure Telemonitoring : Analysis of CARDIAUVERGNE's Cohort","Weigh-HF","Inclusion Criteria:\n\n* adults\n* able to read and understand french\n* included in CARDIAUVERGNE telemonitoring program from 1st january 2023 to 31st december 2024 such as defined by the french health authorithy criteria (heart failure within 12 months or dyspnea at least NYHA 2 associated with NTproBNP of at least 1000pg\u002FmL) and excluded by medical decision as no longer presenting eligibillity criteria\n\nExclusion Criteria:\n\n* Patients leaving telemonitoring for other reasons (choice, death, medical reason, relocation, inobservance)",{"count":123,"type":22},130,"CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. The patients were included from 1st January 2023 to 31st December 2024 and the monitoring was terminated for end of eligibility according to the French health authority criteria.",[126],"Heart Failure",[128,129],"heart failure","telemonitoring",{"date":82,"type":33},{"date":132,"type":33},"2025-12-05",{"date":134,"type":22},"2026-12",{"name":39,"class":40},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":52,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":41},"100537925","qct-in-als-diagnosis-mechanistic-understanding-and-follow-up-100537925","NCT06284161","QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up","Contribution of the Combined Quadriceps Test (QCT) in the Diagnosis, Mechanistic Understanding and Follow-up of Amyotrophic Lateral Sclerosis","PEM-SLA","Inclusion Criteria:\n\n* A male or female patient of legal age with suspected ALS (bulbar or spinal) who meets the criteria for \"possible\", \"probable\" or \"definite\" ALS according to the Awaji criteria\n* Able to give informed consent to participate in the research\n* Enrolled in a Social Security plan\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Severe progressive pathology other than ALS.\n* Comorbidities with another neurological disease altering motor skills.\n* Contraindication to trans-cranial magnetic stimulation: epilepsy, pacemaker, intracranial ferromagnetic foreign body (clip, aneurysm, implants)...\n* Chronic alcoholism\n* Cognitive disorders or major incapacity making it impossible to understand the study and sign an informed consent (fronto-temporal dementia, psychiatric conditions of psychotic type, language disorders)\n* Refusal to participate.\n* Patients under legal protection (guardianship, curators, safeguard of justice)",{"count":145,"type":22},30,[54],"Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway and conduction can be identified and quantified by different techniques using motor-evoked potentials (MEP). The combined quadriceps test (QCT) has been developed to assess central and peripheral motor pathway conduction. This test allows to quantify central and peripheral part of a mixed disorder, and to detect physiological hyporeflexia or hyperreflexia which, in the case of suspected ALS, can lead to interpretation problems.\n\nThe evolution of the QCT parameters during the course of pathology will lead to determine the preponderance of an initial central involvement, but also its extension throughout the pathology. The study of these parameters as well as the clinical course of the disease could reveal a correlation between peripheral and central involvement. This link would provide arguments in favor of pathophysiological hypotheses of disease onset and progression. From a prognostic point of view and depending on the quantification of central and peripheral involvement, the QCT would make it possible to characterize the different ALS phenotypes. This phenotypic characterization would help identify prognostic factors at diagnosis.\n\nThe investigators propose a cohort study with the exploration of central motor neuron damage by QCT during the course of ALS in order to provide arguments for a better mechanistic understanding and follow-up of this disease with a poor prognosis.",[149],"Amyotrophic Lateral Sclerosis",[151,149],"Quadriceps Combined Test",{"date":82,"type":33},{"date":154,"type":33},"2022-06-28",{"date":156,"type":22},"2030-06",{"name":39,"class":40},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":52,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100437219","study-of-the-added-value-of-a-transmural-evaluation-in-patients-with-crohns-disease-under-biotherapy-with-close-fecal-calprotectin-follow-up-100437219","NCT04973423","STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP","Deeper","Inclusion Criteria:\n\n* Adult Crohn's disease (age ≥ 18 years)\n* Symptomatic with Crohn's disease activity index (CDAI)\\> 150\n* Presence of objective signs of inflammatory activity (fecal calprotectin\\> 250 AND sign of MRI activity)\n* Requiring treatment with biotherapy according to the investigator\n* Able to give informed consent to participate in research\n* Affiliation to a Social Security scheme.\n\nExclusion Criteria:\n\n* Severe obstructive symptoms\n* Uncontrolled intra-abdominal abscess\n* Isolated anoperineal lesions\n* Prevention of postoperative endoscopic recurrence\n* Temporary or definitive ostomy\n* Total colectomy\n* Contraindication to MRI\n* Pregnant or breastfeeding women\n* Protected adults (curatorship, guardianship, saving justice)\n* Refusal of participation",{"count":166,"type":22},180,[54],"Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can dramatically affect the quality of life of patients. Due to its transmural nature (involvement of the entire thickness of the intestinal wall), it naturally progresses to intestinal destruction (stenosis, fistula) which requires intestinal resection in approximately half of patients during their follow-up. The long-term goal for patients is to maintain a normal life, that is, without symptoms and without intestinal destruction. For this, the short and medium term therapeutic objectives have evolved in recent years. Clinical remission is not a sufficient goal since it has failed to alter the natural history of the disease. The current objective to be achieved is the combination of clinical remission and endoscopic mucosal healing since it is associated with a reduced risk of progression (reappearance of symptoms, hospitalization, intestinal resection). Fecal calprotectin, better accepted than colonoscopy, is a non-invasive biomarker of endoscopic inflammatory activity in CD. The CALM study recently showed that close follow-up with clinical and biological evaluation (assays of CRP and fecal calprotectin), called \"tight control\", associated with therapeutic intensification in the absence of clinical or biological remission, was associated with a better rate of endoscopic mucosal healing at 1 year than follow-up based solely on symptoms. Thus, the \"CALM\" strategy is considered to be the current benchmark.\n\nTransmural healing evaluated by MRI is also a promising objective associated with a reduced risk of progression (reappearance of symptoms, hospitalization, bowel resection). In addition, it could prevent intestinal destruction. A recent study by our team suggested that calprotectin (mucosal assessment) and MRI (transmural assessment) may be complementary and be a better therapeutic goal. We hypothesize that a \"CALM + MRI\" strategy concomitantly targeting transmural healing would be superior to the \"CALM\" strategy alone in maintaining clinical remission without corticosteroids in patients with CD treated with biotherapies.",[105,170,106],"Calprotectin",{"date":82,"type":33},{"date":173,"type":33},"2022-03-21",{"date":175,"type":22},"2027-08-21",{"name":39,"class":40},17,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":52,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":41},"100649846","diagnosis-of-hidden-hearing-loss-in-adults--refining-the-audiological-profile-for-better-diagnosis-100649846","NCT07738549","Diagnosis of Hidden Hearing Loss in Adults : Refining the Audiological Profile for Better Diagnosis.","SURDICACH","Inclusion Criteria:\n\nAdult patients (age \\> 18 years). Patients affiliated with a social security\u002Fhealth insurance system. Patients consulting the ENT department for hearing difficulties despite normal conventional pure-tone and speech audiometry performed in quiet.\n\nPatients whose native language is French. Patients who have received oral and written information about the study and have provided free and informed consent.\n\nNormal otoscopic examination:\n\nNo external auditory canal obstruction. No history of middle ear surgery (except childhood tympanostomy tube placement).\n\nPresence of a translucent tympanic membrane in at least one quadrant, with no tympanic membrane perforation.\n\nNo signs of active otitis infection. No signs of cholesteatoma. Well-ventilated middle ear cavity confirmed by conventional tympanometry at 226 Hz.\n\n\\- Inclusion criteria for the control group:\n\nAdult patients aged between 18 and 25 years. Patients seen during an ENT consultation at Clermont-Ferrand University Hospital, without any hearing complaints.\n\nPatients with normal conventional pure-tone audiometry performed in quiet, defined as hearing thresholds between 0 and 20 dB HL across frequencies from 0.25 to 8 kHz, according to BIAP 2017 criteria.\n\nNo selection bias is expected, as normal hearing is defined as hearing thresholds between 0 and 20 dB HL (BIAP 2017). This age range was selected because it provides the highest likelihood of including individuals with normal auditory function.\n\n-Exclusion criteria :\n\nPatients under legal guardianship, curatorship, judicial protection, or deprived of liberty.\n\nPregnant or breastfeeding women. History of language disorders.\n\nAbnormal pure-tone audiometry in quiet, defined as:\n\nMean pure-tone hearing loss \\> 20 dB HL, or At least one frequency threshold \\> 20 dB HL.\n\nAbnormal speech audiometry, defined as:\n\nSpeech reception threshold on Lafon disyllabic word lists (male voice) \\> 20 dB HL, and\u002For Maximum speech intelligibility score of 100% obtained at a level \\> 40 dB HL. Refusal to participate in the study.",true,{"count":187,"type":22},80,[54],"This study aims to investigate the underlying mechanisms of speech-in-noise difficulties in patients with normal conventional pure-tone and speech audiometry. Participants presenting with complaints of impaired speech understanding in noisy environments will undergo a comprehensive audiological assessment, including extended high-frequency audiometry, electrocochleography (EcoG), distortion product otoacoustic emissions (DPOAEs), auditory brainstem responses (ABR), and central auditory processing evaluation. The study seeks to identify cochlear, neural, and central auditory abnormalities that may contribute to hidden hearing loss and improve its clinical characterization.",[191,192],"Surdity","the Audiological and Electrophysiological Profile of Hidden Hearing Loss","NOT_YET_RECRUITING","2026-07-27",{"date":84,"type":33},{"date":197,"type":22},"2026-07-01",{"date":199,"type":22},"2027-07-01",{"name":39,"class":40},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":185,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":52,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":41},"100621947","study-of-obstacles-and-barriers-to-changing-risky-eating-behaviors-in-families-of-children-with-severe-early-childhood-caries-qualikids-100621947","NCT07377240","Study of Obstacles and Barriers to Changing Risky Eating Behaviors in Families of Children With Severe Early Childhood Caries (QUALIKIDS).","Study of Obstacles and Barriers to Changing Risky Eating Behaviors in Families of Children With Severe Early Childhood Caries (SECC): a Qualitative Approach (QUALIKIDS)","QUALIKIDS","Inclusion Criteria:\n\n* All parents of children under 6 years of age with CPE-S, consulting the specialized dental care unit as part of the Handiconsult ARA Ouest program for complete conservative oral rehabilitation under general anesthesia\n* Verbal agreement from the participant to take part in the study and for audio recording\n* Parents who understand and speak French.\n\nExclusion Criteria:\n\n* Parents of children in foster care.\n* Parents under judicial protection, guardianship, or conservatorship.\n* Parents who refuse to participate in the study.",{"count":145,"type":22},[54],"Dental caries is the most common chronic disease in children, and its early form-Early Childhood Caries (ECC)-which particularly affects children under the age of six, represents a major public health problem worldwide. This disease has a negative impact on the quality of life of affected children and their families, and leads to significant functional and developmental consequences. Moreover, due to their young age, these children require specialized care and adapted treatment procedures, particularly the use of general anesthesia (GA) for comprehensive oral rehabilitation.\n\nThis conservative therapeutic approach improves the quality of life and orofacial functions of the children concerned, particularly their masticatory ability. However, there remains a significant rate of caries recurrence within the year following treatment. This is largely due to the difficulty families face in changing the dietary habits that contribute to the disease, such as the frequent consumption of sugar-rich foods in all their forms. These families are often bio-psycho-socially vulnerable and have a low level of oral health literacy. They also tend to show lower adherence to preventive measures (oral hygiene practices and regular dental check-ups for children) as well as to the health education and therapeutic interventions proposed to them.\n\nIn order to stabilize dental caries in these children, prevent repeated procedures due to recurrent caries, and offer interventions tailored to their needs, it is essential to better understand why oral health behaviors are so difficult to change within these families. This study aims to adopt a qualitative approach to explore the obstacles and barriers to modifying etiological behaviors, particularly dietary behaviors, in families of young children with severe ECC treated under general anesthesia in the specialized care unit of Handiconsult ARA Ouest (CHU Estaing Clermont-Ferrand - CH Riom). Semi-structured, face-to-face interviews conducted with one or both parents will investigate the different dimensions of this issue. A subgroup analysis will compare the factors influencing the adoption of oral health-promoting habits in families of children with and without associated developmental disorders.",[213],"Early Childhood Caries",{"date":215,"type":33},"2026-07-28",{"date":217,"type":33},"2026-07-10",{"date":219,"type":22},"2028-07",{"name":39,"class":40},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":17,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":41},"100648367","compare-the-intensity-of-pain-felt-by-children-during-the-local-anesthesia-procedure-to-that-perceived-by-the-accompanying-parent-100648367","NCT07718477","Compare the Intensity of Pain Felt by Children During the Local Anesthesia Procedure to That Perceived by the Accompanying Parent.","ADDenT","Inclusion Criteria:\n\n* Children aged 6 to 15\n* Children requiring dental treatment involving local anaesthetic\n* Children accompanied by at least one parent (or legal guardian)\n* Children and parents who speak French fluently\n\nExclusion Criteria:\n\n* Children under the age of 6 (complex self-assessment)\n* Children over the age of 15 (no longer fall within the scope of paediatric dentistry)\n* Children or accompanying parents who have difficulty understanding due to a limited command of French or any form of intellectual disability\n* Children whose parents have not consented to their participation in the study\n* Children who do not wish to participate in the study\n* Unaccompanied children\n* Children with an intolerance or allergy to local anaesthetics, vasoconstrictors or excipients","6 Years","15 Years",{"count":231,"type":22},100,"The goal of this observational study is to compare the intensity of pain experienced by children (aged 6 to 15) during local anaesthesia with that perceived by the parent accompanying them. The main question it aims to answer is:\n\nCan a parent help assess their child's pain when the child is unable to assess it themselves? A preliminary study carried out in the dentistry department of Clermont-Ferrand University Hospital in 2019 showed that parents could be effective external assessors in distinguishing between pain and anxiety in their own children, whom they know well, and were better at this than dentists, who are more prone to errors of judgement.13 This pilot study covered several dental procedures, including pulpotomy, extraction of a primary tooth, curettage of a carious lesion and dental anaesthesia. The study yielded interesting results but also contained some biases, so the investigators would like to improve upon it. To do so, the focus here is on a single therapeutic procedure: local anaesthesia, which is one of the procedures most feared by children and, very often, by the parents accompanying them as well.\n\nOnce consent has been obtained from both parents (or legal guardians), two questionnaires will be used. The first will consist of simple questions and will be aimed at the children (9 items). The second (20 items) will be for parents and will provide additional information on the child's state of health and on the parents' anxiety regarding their own dental care and that provided to their child. The main aim of both questionnaires will be to assess the intensity of pain perceived by the child during the administration of local anaesthesia, with the child self-reporting their pain and the parent providing an external assessment. These questionnaires will be completed every Wednesday, which allows a child (requiring multiple treatments) to complete the questionnaires several times, thereby enabling us to observe changes in the pain perceived by the child and their accompanying parent over the course of successive anaesthetic procedures.",[234,235],"Dental Pain","Dental Anxiety",[237,238,239,240,241],"pediatric odontology","dental pain assessment","anxiety","children","parents","2026-07-17",{"date":244,"type":33},"2026-07-22",{"date":197,"type":22},{"date":247,"type":22},"2028-07-01",{"name":39,"class":40},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":52,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100647230","evaluation-of-a-french-hospital-discharge-therapeutic-education-program-by-nurses-for-heart-failure-patient-edusor-100647230","NCT07706543","Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)","Evaluation of a Therapeutic Patient Education Program for Discharge (ETPsh) by Nurses in a French Hospital Setting Among Patients With Heart Failure","EDUSOR","Inclusion Criteria:\n\n* Patient aged 18 years old or more,\n* Fluent in spoken and written French,\n* Willing to participate in the study,\n* Hospitalized for heart failure in one of the participating centers for at least 2 days,\n* Affiliated with a French social security scheme\n* Discharged either to home or transferred to a Medical and Rehabilitation Care unit.\n\nExclusion Criteria:\n\n* Hospitalized for a reason other than heart failure,\n* Previously included in the study during a prior hospitalization,\n* Presenting with identified cognitive impairment,\n* In a situation deemed inappropriate by the care team (end of life),\n* Living in an institutional setting,\n* Pregnant women,\n* Breastfeeding women,\n* Under legal protective measures,\n* Enrolled in another interventional research study that may interfere with the results of the present study, according to the investigator's judgment.",{"count":258,"type":22},412,[54],"Heart failure affects 2.3% of the adult French population. Readmission within 30 days doubles the risk of early death within the following 30 to 60 days, as well as the risk of rehospitalization over the subsequent two years. Incorporating nurse-led discharge education can significantly reduce readmissions for heart failure as well as all-cause readmissions. Drawing on practices from English-speaking countries and Switzerland regarding patient discharge education at hospital, we propose to evaluate a discharge education program in the French hospital setting for patients with heart failure.\n\nThe objective of this multicenter before-and-after study is to evaluate the impact of a nurse-led discharge education delivered at hospital on the quality of the care pathway for patients with heart failure, assessed 30 days after hospital discharge. The primary outcome is the reduction in 30-day unplanned all-cause hospital readmissions, including emergency department visits. An informal (non-professional) caregiver may also be enrolled in the study if identified by the patient and present during the hospitalization.\n\nPatients enrolled before implementation of the discharge education will constitute the control group (standard therapeutic patient education group). They will receive usual hospital care, including educational sessions throughout hospitalization covering the disease, treatments, and self-care, as well as a follow-up consultation with a nurse 30 days after hospital discharge. This usual care is referred to as standard therapeutic patient education and does not include a structured therapeutic patient education intervention at hospital discharge.\n\nPatients receiving the discharge education will constitute the intervention group (standard therapeutic patient education with discharge education group). They will receive the same usual care (i.e., standard therapeutic patient education and the 30-day post-discharge nurse follow-up consultation), supplemented by the nurse-led discharge education intervention during their hospitalization.\n\nTo minimize the risk of contamination (diffusion bias), the control group will be enrolled and complete follow-up before nurses receive training in the discharge education intervention.",[126],[263,264,265,266,267],"Heart failure","Discharge education","Nurses","Therapeutic education as topic","Readmission",{"date":269,"type":33},"2026-07-15",{"date":86,"type":22},{"date":272,"type":22},"2028-04",{"name":39,"class":40},3,{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":41},"100645605","primary-parkinsonian-pain-clinical-association-and-phenotype-100645605","NCT07702266","Primary Parkinsonian Pain: Clinical Association and Phenotype","PHENOPAIN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* French-speaking.\n* Diagnosis of Parkinson's disease confirmed by a neurologist.\n\nExclusion Criteria:\n\n* Atypical parkinsonian syndrome.\n* Patients under legal protection (guardianship, curatorship, or legal safeguard measures).",{"count":283,"type":22},300,"Among the different types of pain observed in Parkinson's disease, primary parkinsonian pain (PPP) is the most severe, the most difficult to treat, but also the least well characterized and the hardest to describe, not only by patients but also by neurologists. Consequently, PPP remains difficult to identify, even for clinicians with expertise in Parkinson's disease.\n\nNevertheless, patients with Parkinson's disease who experience PPP appear to exhibit certain demographic and clinical characteristics that may help distinguish them from other patients, including a poorer motor response to levodopa, a stronger association with sleep disturbances, and cognitive and behavioral features such as impulse control disorders (ICDs). PPP may therefore be associated with a specific disease phenotype supported by distinct pathophysiological mechanisms.\n\nRecently, a disease progression model proposed the existence of a \"Brain-First\" subtype (characterized by disease onset in the brainstem) and a \"Body-First\" subtype (characterized by disease onset in the gastrointestinal system). Several clinical markers appear to distinguish these subtypes, notably the presence of REM sleep behavior disorder (RBD), which has been associated with the Body-First phenotype.\n\nThe association between PPP and RBD, as well as between PPP and the Body-First subtype, has never been investigated. We hypothesize that PPP may be associated with several clinical markers of the Body-First phenotype. Identifying such associations could facilitate the routine clinical diagnosis of PPP and, consequently, improve its management, which remains inadequate at present.\n\nThe primary objective is to assess the proportion of patients with primary parkinsonian pain according to the presence of probable RBD in Parkinson's disease.\n\nThis prospective, cross-sectional, non-interventional category 3 study (RIPH 3) will be conducted in 300 patients. Patients contacted through the France Parkinson Association and interested in participating in the study will be able to access the online questionnaire via a QR code or a web link. Completion of the questionnaire is expected to take no more than 15 minutes. This self-administered questionnaire will include collection of general data (age, sex, disease duration, initial motor symptoms, side of symptom onset predominance, and comorbidities), assessments of pain, migraine, sleep, constipation, olfaction, anxiety and depression and impulse control disorders.",[286],"Parkinson s Disease",[288,289,290],"Parkinson's disease","RBD","pain","2026-07-09",{"date":293,"type":33},"2026-07-14",{"date":111,"type":22},{"date":296,"type":22},"2027-10",{"name":39,"class":40},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":52,"phases":306,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":322},"100488517","prospective-study-of-antiplatelet-and-anticoagulation-therapy-in-hereditary-haemorrhagic-telangiectasia-100488517","NCT05641142","Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia","PROPLACO-Tel","Inclusion Criteria:\n\n* Patient with Rendu-Osler disease with an indication of antiplatelet and\u002For anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)\n* Age \\> 18 years old\n* Patient able to understand and agree to participate in the study\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Patient with an indication of antiplatelet and\u002For anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months\n* Refusal to participate\n* Pregnant woman or who are breast feeding\n* Patients under maintenance of justice, wardship or legal guardianship",{"count":231,"type":22},[54],"The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and\u002For antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).",[309,310],"Hereditary Hemorrhagic Telangiectasia","Rendu Osler Disease",[312,313,314,315],"epistaxis","hemorrhage","anticoagulant therapy","antiplatelet therapy",{"date":217,"type":33},{"date":318,"type":33},"2023-04-07",{"date":320,"type":22},"2029-04",{"name":39,"class":40},18,{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":331,"maxAge":19,"enrollmentInfo":332,"targetDuration":4,"studyType":52,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":274},"100609333","pet-mri-of-reward-system-in-parkinsons-disease-with-rbd-100609333","NCT07213219","PET-MRI of Reward System in Parkinson's Disease With RBD","Exploration of the Reward System in Parkinson's Patients With Paradoxical Sleep Behavior Disorders: a Multimodal Imaging Study","RBD Impulse","Inclusion Criteria:\n\n* Patients aged 45 to 80 years\n* Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria\n* Duration of Parkinson's disease progression ≥ 3 years\n* Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration\n* Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol\n* Patients affiliated with or beneficiaries of a social security system\n* Volunteer patients capable of providing informed consent to participate in the research\n\nExclusion Criteria:\n\n* Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD)\n* Patients with severe depression (Beck Depression Inventory \\\\\\[20\\] (BDI) score \\> 30), apathy (Starkstein scale \\\\\\[21\\] score ≥ 14), cognitive impairment (Montreal Cognitive Assessment \\\\\\[MoCA\\] \\\\\\[22\\] score \\\u003C 25).\n* Patients with impulse control disorders, defined by either of the following:\n\n  * A score of ≥ 6 on the \"Pathological Gambling\" item, ≥ 8 on the \"Compulsive Buying\" item, ≥ 8 on the \"Sexual Behavior\" item, or ≥ 7 on the \"Eating Behavior\" item, and more than one positive response (score \\> 0) on the corresponding QUIP-RS items for Gambling, Compulsive Buying, Sexual Behavior, and Eating Behavior.\n  * A total QUIP-RS score ≥ 10.\n* Patients with severe motor symptoms: patients with an MDS-UPDRS III score \\> 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item ≥ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement\n* Patients under guardianship, curatorship, deprived of liberty, or under legal protection\n* Pregnant or breastfeeding women\n* Patients with contraindications to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances)\n* Refusal to participate","45 Years",{"count":333,"type":22},44,[54],"Impulse control disorders (ICDs) are frequently observed in Parkinson's disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary risk factor for the emergence of ICDs in PD is long-term dopaminergic treatment, but other risk factors, such as rapid eye movement sleep behavior disorder (RBD), have recently been identified. The mechanisms leading to ICDs in PD remain debated, but it has been shown that the dopaminergic mesocorticolimbic pathways play a key role in reward, learning, and reinforcement processes, as well as in the regulation of impulsivity. PET studies using \\[11C\\]raclopride, a tracer that allows evaluation of the postsynaptic availability of dopamine D2\u002FD3 receptors, have demonstrated abnormal sensitization of the mesocorticolimbic dopaminergic system (the reward system), particularly in the ventral striatum, in Parkinson's patients with ICDs when presented with appetitive stimuli or during gambling tasks. However, this has never been studied in patients with and without RBD. Parkinson's patients with RBD may present greater impairment of mesocorticolimbic pathways than those without RBD, particularly abnormal sensitization and postsynaptic modifications of the dopaminergic system, which could predispose patients to the emergence of ICDs when exposed to dopaminergic agonists. Confirming a particular pattern of denervation in Parkinson's patients with RBD that may favor the emergence of ICDs constitutes a personalized medicine approach with a readily identifiable risk marker in routine clinical practice and offers the possibility of adapting the management of these patients.\n\nThe main objective of this study is to investigate the availability of D2 dopaminergic receptors in subcortical structures (particularly the mesocorticolimbic system) in patients with idiopathic Parkinson's disease, depending on the presence or absence of RBD",[337],"Parkinson's Disease (PD)",[339,340,341,342,343,344],"Impulse Control Disorders","Rapid Eye Movement Sleep Behavior Disorder","Parkinson's Disease","Positron Emission Tomography","[¹¹C]raclopride","Magnetic Resonance Imaging","2026-07-07",{"date":347,"type":33},"2026-07-08",{"date":349,"type":33},"2026-05-07",{"date":351,"type":22},"2029-01-01",{"name":39,"class":40},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":185,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":52,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":41},"100510820","effects-of-a-sedentary-behaviors-at-work-on-health-in-emergency-medical-dispatchers-and-codis-operators-secodis-100510820","NCT05931406","Effects of a Sedentary Behaviors at Work on Health in Emergency Medical Dispatchers and CODIS Operators (SECODIS)","Effects of a Sedentary Behaviors at Work on Health in Emergency Medical Dispatchers and CODIS Operators","SECODIS","Inclusion Criteria:\n\n* Emergency medical dispatchers or firefighters from the departmental fire and rescue operational center (CODIS).\n* Person able to give an informed consent to participate in research\n* Affiliated with a Social Security scheme.\n* Being able to use the sit-stand desk and the cycle ergometer\n\nExclusion Criteria:\n\n* Non-affiliated to a health insurance,\n* Protected persons (minors, pregnant women, breastfeeding women, guardianship, curatorship, deprived of freedoms, safeguard of justice),\n* Refusal to participate.",{"count":362,"type":22},36,[54],"The purpose of the study is to study changes in sedentary behavior following a behavioral intervention (sit-and-stand desk, and cycloergometer)",[366,28],"Sedentary Behavior","2026-07-06",{"date":345,"type":33},{"date":370,"type":33},"2024-03-07",{"date":372,"type":22},"2027-06",{"name":39,"class":40},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":52,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":41},"100629190","evolution-of-masticatory-function-orofacial-functions-and-quality-of-life-of-patients-treated-for-cancers-of-the-upper-aerodigestive-tract-rehabilitated-by-maxillofacial-prostheses-100629190","NCT07471451","Evolution of Masticatory Function, Orofacial Functions and Quality of Life of Patients Treated for Cancers of the Upper Aerodigestive Tract, Rehabilitated by Maxillofacial Prostheses.","RMF-CROC","Inclusion Criteria:\n\n* Adult patient who has given their consent\n* Patient with a history of upper aerodigestive tract cancer\n* Cooperative patient\n* Patient affiliated with a Social Security scheme\n* Patient capable of understanding and participating in the study\n* Patient not allergic to the foods being tested\n\nExclusion Criteria:\n\n* Minors\n* Patients treated in the maxillofacial prosthetics clinic of the Odontology Department at Estaing University Hospital in Clermont Ferrand who do not require prosthetic rehabilitation\n* Patients who are unwilling to participate in the study, particularly in attending the various follow-up sessions\n* Patients who do not have a good command of written and spoken French\n* Patients under guardianship, curatorship, or judicial protection\n* Pregnant or breastfeeding patients\n* Patients receiving enteral or parenteral nutrition\n* Patients who have been diagnosed with a recurrence of their cancer and whose prognosis is life-threatening.\n* Patients with cognitive impairment",{"count":382,"type":22},50,[54],"This is a follow-up study of masticatory function, orofacial functions, and quality of life in patients with a history of upper aerodigestive tract cancer who have undergone rehabilitation with maxillofacial prostheses. The main objective of this study is to evaluate changes in masticatory function during a prosthetic rehabilitation program in patients with a history of upper aerodigestive tract cancer.",[386],"Head and Neck Cancer",[388,389,390,391,392,393,394,395],"mastication","chewing","cancer of the upper aerodigestive tract","prosthetic rehabilitation","oral-facial functions","quality of life","oral health","oral quality of life","2026-07-03",{"date":345,"type":33},{"date":399,"type":33},"2026-05-20",{"date":401,"type":22},"2030-05",{"name":39,"class":40},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":411,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":52,"phases":413,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":41},"100646540","phase-4-osteoporotic-fracture-and-lidocaine-plaster-5-for-neuropathic-pain-prevention-100646540","NCT07691359","Osteoporotic Fracture and Lidocaine Plaster 5% for Neuropathic Pain preventioN","Preventive Effect of 5% Lidocaine Plaster on the Development of Neuropathic Pain Following Osteoporotic Vertebral Fracture: A Proof-of-concept, Controlled, Randomized Trial","FLYNN","Inclusion Criteria:\n\n* Male or female participant aged 50 years or older.\n* Diagnosis of osteoporosis established by the treating rheumatologist.\n* Osteoporotic vertebral fracture diagnosed within the previous month.\n* Pain intensity of ≥3 on a numerical rating scale at the fracture site.\n* Able and willing to provide written informed consent.\n* Affiliated with a French health insurance system.\n\nExclusion Criteria:\n\n* Medical or surgical condition considered by the investigator to be incompatible with study participation.\n* Known hypersensitivity to lidocaine, any excipient of the study treatment, or other amide-type local anesthetics.\n* Current treatment with Class I antiarrhythmic agents (e.g., tocainide, mexiletine) or other local anesthetics.\n* Inflamed or damaged skin at the intended application site (e.g., active herpes zoster lesions, dermatitis, or wounds).\n* Pregnant or breastfeeding women.\n* Women of childbearing potential not using an effective contraceptive method.\n* Positive urine pregnancy test for women whose menopausal status cannot be confirmed.\n* Participation in another clinical research study.\n* Individuals under legal protection or deprived of liberty.\n* Refusal to participate.","50 Years",{"count":145,"type":22},[414],"PHASE4","Osteoporotic vertebral fractures may lead to chronic pain with a neuropathic component, which is often underdiagnosed and undertreated in older adults. This proof-of-concept randomized controlled trial aims to evaluate whether early application of a 5% lidocaine plaster can prevent the development of neuropathic pain following an osteoporotic vertebral fracture. Participants will be randomized in a 2:1 ratio to receive either a daily 5% lidocaine plaster plus standard care or standard care alone for 2 months. The primary outcome is the proportion of participants who develop neuropathic pain at 2 months, assessed using the PainDETECT questionnaire.",[417,418],"Osteoporotic Vertebral Fracture","Neuropathic Pain",[420,421,422,423,424,425],"Lidocaine 5% Plaster","Lidocaine Patch","Osteoporosis","Pain Prevention","PainDETECT","DN4","2026-07-02",{"date":347,"type":33},{"date":197,"type":22},{"date":430,"type":22},"2028-10-01",{"name":39,"class":40},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":440,"conditions":441,"keywords":445,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":455,"locationsCount":41},"100646473","impact-of-migration-history-and-social-conditions-on-the-immuno-virological-control-of-hiv-in-migrants-in-france-100646473","NCT07691424","Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France","PrimoAVIH","Inclusion Criteria:\n\n* Adults (≥18 years of age);\n* Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France.\n\nNon-inclusion Criteria:\n\n* Patients who declined to participate in the study;\n* Patients who do not speak French and for whom no interpretere was available\n* Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)",{"count":74,"type":22},"Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival .\n\nThe primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.",[442,443,444],"HIV - Human Immunodeficiency Virus","Socio-economic Status","Migrants",[446,447,448,449,450],"HIV","socio-economic status","vulnerability","immuno-virological status","migrants",{"date":347,"type":33},{"date":269,"type":22},{"date":454,"type":22},"2030-02-15",{"name":39,"class":40},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":473,"locationsCount":41},"100644263","evaluation-of-masticatory-performance-in-patients-with-periodontitis-100644263","NCT07665489","Evaluation of Masticatory Performance in Patients With Periodontitis","PAROCHEW","Inclusion Criteria:\n\n* Patients followed at the university hospital (CHU) with a diagnosis of periodontitis.\n* No objection from the patient to participate in the study.\n* Patients able to speak and understand French.\n\nExclusion Criteria:\n\n* Minors.\n* Patients under legal protection (guardianship, trusteeship, or judicial protection measures).\n* Pregnant or breastfeeding women.\n* Patients who refuse to participate in the study.",{"count":231,"type":22},"The objective of this observational study is to assess the correlation between the severity of periodontal involvement and masticatory performance in patients with periodontitis.\n\nThe secondary objectives are to identify periodontal parameters that may be associated with a reduction in masticatory performance.\n\nThis study includes a single group.\n\nParticipants will be asked to perform a masticatory performance test consisting of chewing a piece of gum for 20 cycles.",[466,467,468],"Periodontitis, Adult","Periodontitis","Oral Disease",{"date":367,"type":33},{"date":86,"type":22},{"date":472,"type":22},"2027-09-01",{"name":39,"class":40},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":52,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":41},"100642636","evaluation-of-the-impact-of-periodontitis-and-its-treatment-on-swallowing-functions-and-oral-quality-of-life-100642636","NCT07651579","Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life","FI-PAROCROC","Inclusion Criteria:\n\n* Patients treated at the university hospital and diagnosed with periodontitis\n* Adult patients who have provided informed consent\n* Patients enrolled in a social security system\n* Patients who speak and understand French.\n\nExclusion Criteria:\n\n* Minors\n* Pregnant or breastfeeding patients\n* Patients under legal protection or conservatorship\n* Patients who refuse to participate in the study",{"count":333,"type":22},[54],"The objective of this single-center prospective study is to evaluate the impact of periodontal treatment on masticatory performance in patients with periodontitis.\n\nParticipants will be asked to complete several questionnaires related to their oral health and quality of life. Functional masticatory tests and salivary flow measurements will also be performed.",[467,485,486],"Periodontal Diseases","Quality of Life",{"date":367,"type":33},{"date":86,"type":22},{"date":490,"type":22},"2028-09-01",{"name":39,"class":40},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":499,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":52,"phases":501,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":41},"100645316","plant-based-diet-in-older-people-what-consequences-for-muscle-health-100645316","NCT07681986","Plant-based Diet in Older People: What Consequences for Muscle Health?","MYOVEG","Inclusion Criteria:\n\n* Men and women aged 65 years and older\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm² (exclusive)\n* Physical activity \\\u003C 3000 MET-min\u002Fweek, assessed using the ONAPS-PAQ questionnaire\n* Laboratory tests compatible with participation in the study\n* Adequate venous status, as assessed by study nurses, allowing catheter placement\n* Willingness to participate in study procedures, including indirect calorimetry, functional tests, and assigned dietary intervention (plant-enriched or standard diet)\n* Affiliation with the French Social Security system\n\nExclusion Criteria:\n\n* Men and women aged 65 years and older\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm² (exclusive)\n* Physical activity \\\u003C 3000 MET-min\u002Fweek, assessed using the ONAPS-PAQ questionnaire\n* Laboratory tests compatible with participation in the study\n* Adequate venous status, as assessed by study nurses, allowing catheter placement\n* Willingness to participate in study procedures, including indirect calorimetry, functional tests, and assigned dietary intervention (plant-enriched or standard diet)\n* Affiliation with the French Social Security system\n* Exclusion period from a previous study or total compensation exceeding €6,000 in the 12 months prior to study initiation (verified through the National Research Volunteer Database)\n* Patients under legal guardianship, curatorship, deprived of liberty, or under judicial protection\n* Claustrophobia","65 Years",{"count":99,"type":22},[54],"This randomized, controlled, two-arm clinical study aims to determine how increasing the proportion of plant-based foods in the diet affects skeletal muscle strength, mass and function, protein metabolism, microbiota and key metabolic markers in healthy older men and women. We hypothesize that diets enriched with animal-based foods will maintain maximal quadriceps strength-the primary outcome of the study-more effectively after the 3-month nutritional intervention than plant-based diets. Proteomic analyses will be performed to identify molecular mechanisms and potential muscle biomarkers reflecting metabolic adaptations of skeletal muscle to plant-enriched diets. In addition, metabolic health markers and micronutrient status will be evaluated to better understand the overall health effects of dietary plant-based transition in older adults.",[504],"Aging",[504,506,507,508,509,510,511,512,513,514],"Older Adults","Plant-Based Diet","Muscle Strength","Skeletal Muscle","Protein Metabolism","Physical Performance","Proteomics","Body Composition","Gut Microbiota","2026-06-26",{"date":426,"type":33},{"date":518,"type":22},"2026-07-20",{"date":520,"type":22},"2030-08",{"name":39,"class":40},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":41},"100645173","study-of-the-frequency-and-characteristics-of-pain-symptoms-in-restless-legs-syndrome-100645173","NCT07679087","Study of the Frequency and Characteristics of Pain Symptoms in Restless Legs Syndrome","PAIN-RLS","Inclusion Criteria:\n\n* Male or female participants aged 18 years or older.\n* Diagnosis of Restless Legs Syndrome (RLS) according to the criteria of the International Classification of Sleep Disorders, Third Edition (ICSD-3).\n* French-speaking.\n\nExclusion Criteria:\n\n* Patient under guardianship, curatorship, or legal protection measures.\n* Patient who has never had an appointment with a neurologist as part of their SJSR care pathway.",{"count":530,"type":22},1000,"Restless Legs Syndrome (RLS) is a neurological disorder affecting between 4% and 29% of adults. It is characterized by an urge to move the legs or other parts of the body, often accompanied by unpleasant and sometimes painful sensations. The pathophysiology of RLS, whether associated with pain or not, remains poorly understood, and only a limited number of studies have specifically investigated this aspect.\n\nThe aim of this study is to determine the prevalence of the painful component of symptoms in a large cohort of patients with RLS, to further characterize its clinical features, and to assess its impact on patients' quality of life. This work could improve the identification of patients experiencing pain, enhance our understanding of pain characteristics in RLS, and help optimize patient management. Furthermore, in the context of emerging therapeutic approaches such as neuromodulation, a better characterization of pain in RLS may contribute to the development and evaluation of new treatment strategies. This is particularly relevant given the high prevalence of RLS and its substantial impact on patients' quality of life.\n\nParticipants will be recruited either through their neurologist during routine follow-up visits at the Neurology Department of Clermont-Ferrand University Hospital or through the France Ekbom Association. Individuals interested in participating will be provided with access to the online questionnaire via a QR code or a dedicated web link. One thousand patients will be include in this study (RIPH type 3). The online questionnaire is expected to take approximately 30 minutes to complete. It includes the collection of demographic data (age, sex, lifestyle factors, weight, height, employment status, comorbidities, and dietary habits), as well as questions regarding the patient's medical history and sleep habits.\n\nThe questionnaire also includes validated instruments assessing sleep, pain, RLS severity, anxiety and depression, and quality of life.\n\nAt the end of the questionnaire, participants will be invited to take part in an optional ancillary study aimed at validating the French translation of the Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL). Participants who agree to participate will complete the questionnaire once at baseline and will subsequently receive an email reminder to complete it a second time two weeks later. This test-retest procedure will be used to assess the reproducibility of the French-adapted version of the questionnaire.",[533],"RLS",[533,535,536],"Pain","Sleep","2026-06-25",{"date":197,"type":33},{"date":540,"type":22},"2026-07",{"date":542,"type":22},"2027-08",{"name":39,"class":40},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":52,"phases":553,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":41},"100644014","a-study-of-the-impact-of-a-virtual-reality-medical-device-hypnovr-headset-on-anxiety-and-pain-in-interventional-radiology-100644014","NCT07668050","A Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.","HYPNO-VR","Inclusion Criteria :\n\n* Age ≥18 years.\n* Scheduled to undergo an interventional radiology procedure performed under local anesthesia without sedation.\n* Affiliation to a health insurance system.\n* Received complete information about the study and provided written informed consent.\n* Ability to understand the study information and complete the questionnaires.\n\nExclusion Criteria :\n\n* Refusal to participate or withdrawal of consent.\n* Patients under legal protection preventing valid informed consent according to regulatory requirements.\n* Inability to understand study-related information or to use the virtual reality device due to severe visual, auditory, or cognitive impairment, as clinically assessed by the investigator.\n* History of photosensitive epilepsy or uncontrolled epilepsy, constituting a contraindication to virtual reality use.\n* Known contraindication to virtual reality use (history of severe cybersickness).",{"count":552,"type":22},70,[54],"Patients undergoing interventional radiology procedures frequently experience significant anxiety and procedural pain despite standard care. Virtual reality (VR) has emerged as a promising non-pharmacological tool for anxiety and pain reduction in various medical settings.\n\nThe HYPNO-VR study is a prospective randomized controlled trial designed to evaluate the effect of immersive virtual reality during interventional radiology procedures. Participants will be randomized in a 1:1 ratio to either a virtual reality group or a standard care control group.\n\nThe primary objective is to assess the impact of VR on procedural anxiety and pain using validated anxiety questionnaires (State-Trait Anxiety Inventory, STAI) and a numerical pain rating scale.\n\nSecondary and exploratory objectives include assessment of patient satisfaction, operator experience, procedural duration, analgesic use, and feasibility of VR integration in interventional radiology practice.",[556,535,557],"Anxiety","Radiology, Interventional",[559,560,561,562,563,564,565,566],"Virtual Reality","Interventional Radiology","State-Trait Anxiety Inventory","Patient Satisfaction","Non-pharmacological Intervention","Immersive Virtual Reality","Procedural Anxiety","Procedural Pain",{"date":568,"type":33},"2026-06-29",{"date":570,"type":22},"2026-06",{"date":134,"type":22},{"name":39,"class":40},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":52,"phases":582,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":595},"100644021","phase-1-fecal-transplantation-in-hidradenitis-suppurativa--a-pilot-study-100644021","NCT07668713","FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study","FESTIVAL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with Hurley HS II (moderate severity) or III (very severe)\n* Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula\n* Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment.\n\nExclusion Criteria:\n\n* Allergy or contraindication to amoxicillin-clavulanic acid\n* Patient having received biomedication in the 3 months prior to inclusion\n* Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease)\n* Concomitant Clostridioides Difficile infection\n* Immunocompromised patients\n* HIV infection and active HBV\u002FHCV hepatitis\n* No health insurance\n* Pregnant or breast-feeding women\n* Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort)\n* Patients under guardianship\u002Fcuratorship\u002Flegal protection",{"count":581,"type":22},24,[583],"PHASE1","The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota.\n\nTranslated with DeepL.com (free version)",[586,587],"Hidradenitis Suppurativa (HS)","Fecal Microbiota Transplantation (FMT)","2026-06-23",{"date":537,"type":33},{"date":591,"type":22},"2026-06-01",{"date":593,"type":22},"2031-06",{"name":39,"class":40},7,{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":604,"minAge":605,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":52,"phases":607,"briefSummary":609,"conditions":610,"keywords":613,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":621,"leadSponsor":623,"locationsCount":274},"100643903","phase-2-functional-brain-mri-to-understand-pain-phenotypes-in-knee-osteoarthritis-100643903","NCT07668674","Functional Brain MRI to Understand Pain Phenotypes in Knee Osteoarthritis","Functional Brain MRI to Understand Pain Phenotypes in Knee Osteoarthritis: a Multicenter Comparative Pilot Study","INDIGO","Inclusion Criteria:\n\n* Women aged 40 or older (only women will be included to ensure consistency in the analyses, given the higher prevalence of osteoarthritis in women and the influence of sex\u002Fgender on the experience of pain)\n* Diagnosis of femorotibial osteoarthritis of the knee according to the 1986 American College of Rheumatology criteria\n* Presence of knee pain with an intensity of ≥ 4\u002F10 on a numerical rating scale (NRS)\n* Chronic knee pain, i.e., lasting at least 6 months with at least 15 days of pain in the past 30 days\n* Completion of the PainDETECT questionnaire, which will allow the patient to be assigned to one of two groups prior to the enrollment visit (those with nociceptive pain \\[score ≤ 12\\] and those with neuropathic pain \\[score \\> 13\\])\n* Patients have read and understood the information letter\n* Patients have signed the informed consent form\n* Patients are enrolled in a social security program\n\nExclusion Criteria:\n\n* Other joint diseases affecting the knees (gout, chondrocalcinosis, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis)\n* Conditions that, in the investigator's opinion, interfere with the assessment of osteoarthritic pain, such as conditions causing neuropathic pain in the lower extremities (e.g., peripheral neuropathy, chronic radiculopathy) or fibromyalgia\n* Kellgren-Lawrence radiographic stage IV in one or both knees\n* Patients with one or more knee prostheses\n* Claustrophobia making MRI impossible\n* Contraindication to MRI\n* Pregnant or breastfeeding women\n* Patients under guardianship, conservatorship, deprived of liberty, or under judicial protection\n* Patients who have participated in an interventional clinical trial within the last 6 months that could impact the primary endpoint","FEMALE","40 Years",{"count":99,"type":22},[608],"PHASE2","Some people with knee osteoarthritis (gonarthrosis) experience pain differently. In some, the pain is described as \"nociceptive\" (directly related to the joint), while in others it has \"neuropathic\" characteristics (related to nerve function).\n\nThe goal of this multicenter, cross-sectional and comparative study is to compare resting brain activity in a brain region called the anterior insula among female patients with painful knee osteoarthritis who experience nociceptive pain compared to those with neuropathic pain.\n\nResearchers will compare brain activity at rest between these two types of pain in women over 40 with painful knee osteoarthritis. A better understanding could help improve pain management in the future.\n\nParticipants will be asked to :\n\n* complete questionnaires during the inclusion visit and on the day of the scan,\n* undergo a clinical examination and a blood test at the inclusion visit,\n* undergo a functional MRI (fMRI), an imaging test that allows observation of brain activity at rest.\n\nPaticipants in the study does not involve any additional treatment. the fMRI scan is non-invasive and does not require any injections.",[611,612],"Gonarthrosis","Neuropathic Pain, Nociceptive Pain",[611,614,615,616,617,618,602],"Neuropathic pain","Nociceptive Pain","Functional MRI","Anterior insula","Brain activity in the anterior insula at rest",{"date":537,"type":33},{"date":540,"type":22},{"date":622,"type":22},"2028-08",{"name":39,"class":40},""]